Fatality Associated With Combined Fluoxetine-Amitriptyline Therapy

JAMA: The Journal of the American Medical Association

Volumn 277, Issue 21, 1997, Pages 1682-

  Preskorn, Sheldon H ^a   Baker, Bryan ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; FLUOXETINE; NORFLUOXETINE; NORTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; CASE REPORT; DEPRESSION; DRUG CLEARANCE; DRUG FATALITY; DRUG MIXTURE; FATALITY; HUMAN; LETTER; MALE; PRIORITY JOURNAL;

EID: 0030921915     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1997.03540450038031     Document Type: Letter

References (4)

1. Preskorn SH, Fast G. Therapeutic drug monitoring for antidepressants: safety, efficacy, and cost-effectiveness. J Clin Psychiatry. 1991;52:23-33.
2. Prouty RW, Anderson WH. Postmortem redistribution of drugs. In: The International Association of Forensic Toxiologists: Proceedings of the 24th International Meeting, July 28-31, 1987. Edmonton, Alberta: International Association of Forensic Toxicologists; 1988:1-21.
3. Apple FS, Bandt CM. Liver and serum postmortem tricyclic antidepressant concentrations. In: The International Association of Forensic Toxicologists: Proceedings of the 24th International Meeting, July 28-31, 1987. Edmonton, Alberta: International Association of Forensic Toxicologists; 1988:55-69.
4. Harvey AH, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors, I and II. J Clin Psychopharm. 1996;16:273-285.